Abdera Therapeutics Inc. has revealed that the U.S. Food and Drug Administration has approved their Investigational New Drug application for ABD-147.

Aulos Bioscience revealed preliminary outcomes from its Phase 1/2 study of AU-007.

May 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Celltrion gains European Commission approval for Omlyclo® (CT-P39), the first omalizumab biosimilar sanctioned in Europe.

Recent advancements in Alzheimer's treatment are promising, with Biogen and Eisai's Leqembi receiving full approval in July, and EliLilly's donanemab potentially following suit soon.

Phase I clinical trial results for Amgen’s experimental weight-loss drug, MariTide, indicate it may provide longer-lasting effects compared to existing glucagon-like peptide-1 (GLP-1) treatments such as Novo Nordisk’s Wegovy and EliLilly’s Zepbound.

Vividion Therapeutics, a subsidiary of Bayer AG, has commenced a Phase I clinical trial for VVD-130850, an oral STAT3 inhibitor intended to treat advanced solid and hematologic tumors.

Thermosome has received approval from the Data Safety Monitoring Board (DSMB) to continue with the planned dosage increase in its Phase I clinical trial for THE001.

MiNK Therapeutics's primary product, AGENT-797, is currently undergoing multiple Phase 1 clinical trials, with anticipated results to be released later this year.

Prokarium has initiated a Phase I/Ib clinical trial, known as PARADIGM-1, for non-muscle invasive bladder cancer (NMIBC) patients.

REGENXBIO has successfully completed patient recruitment for the second group in the Phase I/II AFFINITY DUCHENNE® clinical trial, which is examining the safety and effectiveness of RGX-202.

REGENXBIO Inc. (Nasdaq: RGNX) revealed that the Phase I/II/III CAMPSIITE® clinical trial for RGX-121, a treatment for Mucopolysaccharidosis Type II (MPS II).